TORONTO, Oct. 31, 2025 /PRNewswire/ — Visionary Holdings Inc. (hereinafter referred to as the “Company”; a diversified enterprise registered in Ontario, Canada and listed on the Nasdaq Capital Market under the ticker symbol: GV) successfully held its 2025 Annual General Meeting (AGM) via Zoom video conference from 10:00 a.m. to 12:00 p.m. ET (UTC-4) on the same day. Chaired by Mr. Robert Jay LEES, the voting rights represented by attending shareholders and their proxies accounted for 97.79% of the company’s total voting rights, far exceeding the quorum requirements stipulated in the Business Corporations Act (Ontario, 1990), Nasdaq Listing Rules, and the company’s Articles of Association. The meeting’s convening procedures and agenda items were in compliance with laws and regulations, fully safeguarding shareholders’ rights to participation and voting.

During the meeting, shareholders and their proxies conducted in-depth discussions on core agenda items including board renewal, reappointment of auditors, and review of the annual report. Eventually, all proposals were approved with an overwhelming majority, laying a solid institutional foundation for the company’s governance enhancement and business layout in the next fiscal year.

I. Renewal of the 4th Session of the Board of Directors: Professional Team to Support Strategic Implementation

As the core agenda of this meeting, the Company strictly adhered to the U.S. SEC’s director independence standards and Nasdaq’s mandatory rule of “a majority of independent directors (≥50%)”. The Nomination Committee, through public solicitation and multiple rounds of interview evaluations, selected 16 qualified candidates (including 9 incumbents and 7 new members) from 18 candidate profiles, covering key fields such as corporate management, financial management, legal compliance, international education, high-end medical aesthetics and big health, and biotechnology.

Based on the statistics from the dual voting mode of “on-site voting + email voting”, 9 candidates – Mr. William T. Chai, Mr. Kealey Donald M, Mr. Jun Huang, Mr. Rusheng Wu, Mr. Robert Jay LEES, Ms. Jiena Zhang, Mr. Weixing Wang, Mr. Yi Wang and Mr. Henry Sun – were officially elected as members of the 4th Session of the Board of Directors, having received more than two-thirds of the affirmative votes from the valid voting rights of attending shareholders. Their term will run from the effective date of the resolution of this AGM to the end of the 2026 Annual General Meeting.

With their cross-sector professional backgrounds and rich practical experience, the new board members will provide diverse perspectives for the company’s strategic decision-making, further optimize the governance structure, and effectively safeguard the long-term interests of all shareholders.

II. Reappointment of Auditors: Strengthening the Defense Line of Financial Compliance

To meet the stringent audit supervision requirements of the U.S. SEC and Nasdaq for listed companies, the meeting approved the Proposal on the Appointment of Auditors for the 2025-2026 Fiscal Year, agreeing to reappoint Assentsure PAC as the company’s auditor for the 2025-2026 fiscal year (April 1, 2025 to March 31, 2026).

Assentsure PAC has completed registration with the U.S. Public Company Accounting Oversight Board (PCAOB) and holds the legal qualification to provide audit services for U.S.-listed companies. During the 2024-2025 fiscal year audit work, its core team, supported by over 6 years of cross-border audit experience, efficiently completed the financial statement audit and internal control evaluation. The audit conclusions truly reflected the company’s financial status, and its professional capabilities have been recognized by the company and shareholders. After this reappointment, Assentsure PAC will continue to be responsible for statutory matters such as the company’s annual financial statement audit and SEC periodic report audit. The audit service fee will remain consistent with the previous fiscal year (excluding audit travel expenses and fees for additional matters), ensuring that the company’s financial information disclosure is “true, accurate, complete, timely and fair”.

III. Review of Annual Reports: Clarifying Operating Results and Development Path

The meeting approved the 2024-2025 Fiscal Year Financial Report and 2024-2025 Fiscal Year Board of Directors’ Work Report with an overwhelming majority, conducting a comprehensive review of the company’s operating performance and strategic progress in the past fiscal year (April 1, 2024 to March 31, 2025):

Financial Performance: The revenue of the company’s core businesses (real estate, education, and big health) accounted for 78%. The net profit of the new business (big health projects) achieved a year-on-year growth of 100%, demonstrating remarkable results in business transformation. Total assets remained stable at USD 68,792 thousand, and the asset-liability ratio was controlled at 80%, maintaining a sound financial structure and providing sufficient resilience for future development.

Business and Governance Progress: On the market front, the company established branches in China, added more than 30 new clients, maintained customer satisfaction at over 80%, and continuously enhanced its international brand influence. On the strategic front, it deployed in the fields of artificial intelligence and big health, completed the acquisition of the Changle Shuang Big Health Project and the strategic investment in the new energy vehicle project, expanding its growth tracks. On the governance front, it revised the Articles of Association and Rules of Procedure for the Board of Directors, strengthened internal control and risk management, and further improved its compliant operation capabilities.

The reports clearly stated that in the next fiscal year, the company will focus on three major goals: “improving the quality of core businesses, accelerating the development of emerging businesses, and strengthening compliant governance”, increase R&D investment and talent development, and promote high-quality business development.

IV. Confirmation of Statutory Matters: Consolidating the Foundation for Compliant Operations

To ensure the legality and continuity of the company’s governance, the meeting reviewed and approved three key statutory matters:

1.Confirmed the legality and validity of the election results for the 4th Session of the Board of Directors, verifying that the qualifications of the new board members comply with the requirements of laws, regulations and the company’s Articles of Association;

2.Confirmed the validity of the appointment of Assentsure PAC as the company’s auditor for the 2025-2026 fiscal year, and clarified its audit responsibilities and service scope;

3.Approved the 2024-2025 Fiscal Year Form 20-F, ensuring that the annual report submitted by the company to the U.S. SEC complies with information disclosure regulatory requirements.

V. Follow-up Arrangements: First Meeting of the 4th Session of the Board of Directors to Be Held Soon

In accordance with the resolution of this AGM, the first meeting of the 4th Session of the Board of Directors will be held via Zoom video conference at 10:00 a.m. on November 3, 2025 (ET). The core agenda will include: electing the Chairman of the Board, Executive Directors, and Secretary of the Board; determining the members of the four special committees (Audit, Nomination, Remuneration, and Investment); and appointing the senior management team including CEO, Co-CEO, CFO, and Vice Presidents. The relevant meeting resolutions will be disclosed through the “Investor Relations” section on the company’s official website (www.visionary.holdings) within 48 hours after the meeting, ensuring that shareholders are promptly informed of the company’s governance developments.

The Board of Directors of Visionary Holdings Inc. stated: “The successful convening of this Annual General Meeting has injected new governance momentum into the company. The 4th Session of the Board of Directors will take ‘being responsible to shareholders and seeking development for the company’ as its core, diligently perform its duties, deepen business innovation on the basis of compliant operations, continuously enhance the company’s core competitiveness, and create long-term and stable value returns for all shareholders.”

SINGAPORE, Oct. 31, 2025 /PRNewswire/ — JoyLogistics, the supply chain solutions arm of JINGDONG Logistics (JD Logistics), announced the launch of its integrated delivery and installation service for bulky items in Malaysia and Singapore. In the core areas of Kuala Lumpur, a next-day delivery service can be provided upon appointment.

Delivering bulkier home appliances or furniture can be more complex than handling standard parcels, with orders often requiring in-home placement or professional installation.

To address these challenges and ensure a high standard of customer experience, JD Logistics is offering businesses an integrated one-stop delivery and installation logistics solution. The service provides end-to-end support from doorstep delivery and installation to on-site setup, all completed in a single visit. Customers can also request doorstep returns and exchanges, ensuring a seamless, reliable, and worry-free experience.

Leveraging its global logistics network, JoyLogistics also provides enterprises with comprehensive 3PL services, including cross-border transportation, local warehousing, outbound fulfillment, last-mile delivery and installation, and reverse logistics.

As the supply chain and logistics arm of JD.com, JINGDONG Logistics has become a world-leading integrated supply chain and logistics service provider. It operates over 3,600 warehouses and can deliver 95% of first-party orders within 24 hours in China. JINGDONG Logistics has established a warehouse-centered global logistics network. To date, the company operates nine overseas warehouses across Southeast Asia, covering Malaysia, Thailand, Singapore, Vietnam, and Indonesia. Within local warehouse cities, it provides same-day and next-day delivery, while cross-border shipments can arrive in as fast as 72 hours.

To further enhance its international capabilities, JINGDONG Logistics is expanding its warehousing, air freight, and express delivery networks across Southeast Asia, empowering businesses and consumers throughout ASEAN with faster, more reliable, and fully integrated logistics solutions.

About JINGDONG Logistics

JINGDONG Logistics (HKEX: 2618), also known as JD Logistics, is a leading technology-driven supply chain solutions and logistics services provider. JINGDONG Logistics has established six highly synergized logistics networks including warehousing, line-haul transportation, last-mile delivery network, bulky items, cold chain logistics, and cross-border logistics networks. Including cloud warehouses operated by third parties, JINGDONG Logistics manages over 3,600 warehouses, with a total area exceeding 34 million square meters. The company currently operates over 130 bonded, direct mail and overseas warehouses, with a total GFA exceeding 1 million square meters, spanning 23 countries and regions worldwide. “JoyLogistics” and “JoyExpress” are JINGDONG Logistics’ international business brands.

SHANGHAI, Oct. 31, 2025 /PRNewswire/ — Shanghai Zhimeng Biopharma Inc. ( “Zhimeng”) announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially initiated the phase 2/3 clinical trial and completed the first patient first dose at the 2nd Affiliated Hospital of Hebei Medical University. Previously (in July 2025), CB03-154 received approval from the China Center for Drug Evaluation (CDE) to conduct the ALS phase 2/3 adaptive clinical trial. The CB03-154 has also been granted orphan drug status in the United States in October 2023 for the treatment of ALS.

This phase 2/3 clinical trial is a multicenter, randomized, double-blind, placebo-controlled study with open-label extension. This study is led by Professor Fan Dongsheng from the 3rd Affiliated Hospital of Peking University as the leading investigator nationwide. This study will enroll approximately 240 patients diagnosed with ALS in about 15 centers in China. The disease duration of to be enrolled patients will be within 24 months from the first symptom onset to the screening visit. The primary efficacy endpoint of the study is the change from baseline at week 39 of the revised ALS Functional Rating Scale (ALSFRS-R) score.

Amyotrophic Lateral Sclerosis (ALS) is a progressive and fatal central nervous system disease with unknown etiology. It mainly affects the motor neurons in the cerebral cortex, brainstem, and spinal cord. The pathological features of ALS include the loss of upper and lower motor neuron cell bodies, as well as the degeneration of the corticospinal tract/corticobulbar tract and axons of lower motor neurons, and the occurrence of denervation changes in muscles. Clinically, it mainly presents as progressive skeletal muscle weakness, atrophy, fasciculation, bulbar palsy, and pyramidal tract signs. The median survival duration is generally 2 to 3 years after the onset of symptoms. The main cause of death is neuromuscular respiratory failure. The annual incidence of ALS in Europe and the United States is 2/100,000 to 3/100,000, and the prevalence rate is 3-5/100,000. The peak age of onset is 50 to 75 years. Approximately 10% of ALS patients are familial, while the remaining 90% are sporadic. Currently, there are no treatments that can stop or reverse the progression of the disease. Therefore, clinical management focuses on early diagnosis and early treatment to maximize the survival time. Currently, only three drugs have been approved worldwide for ALS, namely Riluzole, Edaravone, and Tofersen (trade name Qalsody). These approved drugs can only slightly improve the patient’s function or slightly prolong the survival time. Therefore, ALS still has a huge unmet medical need.

Although the pathogenesis of ALS has not been fully deciphered, studies have found that it is closely related to changes in ion channels, synaptic transmission and connections, as well as the imbalance of excitation and inhibition of neurons. Among them, the potassium ion (K+) channel is the most widely distributed and has the largest variety, mainly participating in regulating the excitability of neurons and the frequency and amplitude of action potential generation. Currently, there are no marketed KCNQ2/3 potassium ion channel openers available for ALS patients. The only KCNQ2/3 potassium ion channel opener that was approved by the FDA and EMA, ritigabine (Potiga, Ezogabine/Retigabine), was once studied in ALS patients and showed a favorable signal. However, due to the risks of pigmentation-induced vision impairment and other risk factors, it was withdrawn from the market in 2017.

CB03-154 is a new generation selective voltage-gated potassium channel (KCNQ2/3) opener, independently developed by Zhimeng. Compared with the first-generation potassium channel opener ritigabine, CB03-154 has superior selectivity and stability. In vitro studies have confirmed that CB03-154 can significantly reduce the excessive excitation of iPSC motor neurons from ALS patients. Moreover, in the SOD-1 ALS transgenic mouse model, daily oral administration of CB03-154 (10 mg/kg) can effectively prolong the survival time, delay the onset, improve motor ability, alleviate neuronal damage, and slow down the rate of muscle atrophy.

The initiation of this Phase 2/3 clinical trial is a significant step for CB03-154 in the field of rare diseases, and it brought hopes to provide an important new treatment option for ALS patients.

About Zhimeng 

Founded in 2018, Shanghai Zhimeng Biopharma, Inc. is a biopharmaceutical company dedicated to develop small-molecule drug discovery with focused on the functional cure of chronic hepatitis B (CHB), as well as novel therapies for CNS disorders, including epilepsy, neuropathic pain (e.g. cancer-related pain), amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and bipolar disorder.

Disclaimer

This press release contains forward-looking statements. While Zhimeng considers the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For more information, please visit: www.corebiopharma.com